Equity Profile

GSK

GSK plc

Health CarePharmaceuticals$101.0B

Apr29Wed

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

GSK plc is a global healthcare company focused on pharmaceuticals, vaccines, and consumer health products. With a market cap of $101 billion, GSK plays a significant role in addressing health challenges worldwide, particularly in the pharmaceutical sector.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, showing how much profit is allocated to each share.

$1.16

Revenue

Revenue reflects the total sales generated by GSK, indicating the company's market performance and growth potential.

$7.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

GSK Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-32.34%

Avg Stock Reaction

-0.73%

Last Quarter Recap

In the last quarter, GSK faced challenges with earnings that fell short of expectations, leading to a notable stock reaction. The company has been focusing on improving its product pipeline and addressing market demands.

Management Promises & Guidance

Commitment to enhancing vaccine production capabilities.
Focus on expanding the consumer health product line.
Plans to streamline operations for better efficiency.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about GSK's upcoming earnings, expecting a slight improvement in both EPS and revenue compared to previous quarters. However, there are concerns about potential challenges in meeting these expectations.

Bull Case

If GSK exceeds EPS and revenue estimates, it could signal strong demand for its products and effective management strategies, leading to a positive stock reaction.

Bear Case

Conversely, if GSK misses its targets, it may raise doubts about its growth trajectory and operational efficiency, potentially resulting in a negative market response.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.16

EPS is a key indicator of the company's profitability and financial health, showing how much profit is allocated to each share.

Revenue

$7.6B

Revenue reflects the total sales generated by GSK, indicating the company's market performance and growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GSK's EPS meet or exceed the consensus estimate of $1.16?

This figure is crucial as it directly reflects the company's profitability and can significantly influence investor sentiment.

What are the revenue expectations compared to the consensus of $7.6B?

Revenue performance will indicate market demand for GSK's products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate GSK's ability to leverage its recent investments in vaccine production, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

The options market is pricing a 9.71% move, indicating higher volatility than historical averages suggest.

GSK's recent product launches may not be fully reflected in current revenue expectations.

Key Risk

If GSK's revenue exceeds $7.7B, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching GSK's ability to meet or exceed these earnings expectations, which will shape future growth narratives.

Bull Confirmed If

An EPS of $1.18 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $1.15 would signal potential issues in profitability and market challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±9.71%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move for GSK's stock, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±9.7% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

25.1%

Calls (39K)P/C Ratio: 2.84Puts (15K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

19.80%

of float

Insider

0.06%

of float

Holders

1,142

institutions

Top Holders· as of Dec 2025

Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GSK beats expectations, history suggests a potential stock increase of around 1.99%, confirming positive market sentiment.

In-Line / Cautious

A cautious in-line report may lead to muted stock movement, as investors weigh management's commentary on future guidance.

Miss

If GSK misses expectations, the stock could decline by approximately 0.83%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on vaccine production capacity and timelines.
2Details on consumer health product sales growth.
3Management's outlook on market conditions and competition.
4Insights into R&D progress and pipeline developments.
5Comments on operational efficiency improvements.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, showing how much profit is allocated to each share.

$1.16

Revenue

Revenue reflects the total sales generated by GSK, indicating the company's market performance and growth potential.

$7.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

GSK Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-32.34%

Avg Stock Reaction

-0.73%

Last Quarter Recap

Management Promises & Guidance

Commitment to enhancing vaccine production capabilities.
Focus on expanding the consumer health product line.
Plans to streamline operations for better efficiency.

Expectations

Wall Street Expectations

Bull Case

If GSK exceeds EPS and revenue estimates, it could signal strong demand for its products and effective management strategies, leading to a positive stock reaction.

Bear Case

Conversely, if GSK misses its targets, it may raise doubts about its growth trajectory and operational efficiency, potentially resulting in a negative market response.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.16

EPS is a key indicator of the company's profitability and financial health, showing how much profit is allocated to each share.

Revenue

$7.6B

Revenue reflects the total sales generated by GSK, indicating the company's market performance and growth potential.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GSK's EPS meet or exceed the consensus estimate of $1.16?

This figure is crucial as it directly reflects the company's profitability and can significantly influence investor sentiment.

What are the revenue expectations compared to the consensus of $7.6B?

Revenue performance will indicate market demand for GSK's products and overall business health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate GSK's ability to leverage its recent investments in vaccine production, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

The options market is pricing a 9.71% move, indicating higher volatility than historical averages suggest.

GSK's recent product launches may not be fully reflected in current revenue expectations.

Key Risk

If GSK's revenue exceeds $7.7B, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching GSK's ability to meet or exceed these earnings expectations, which will shape future growth narratives.

Bull Confirmed If

An EPS of $1.18 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $1.15 would signal potential issues in profitability and market challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±9.71%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move for GSK's stock, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±9.7% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

25.1%

Calls (39K)P/C Ratio: 2.84Puts (15K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

19.80%

of float

Insider

0.06%

of float

Holders

1,142

institutions

Top Holders· as of Dec 2025

Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GSK beats expectations, history suggests a potential stock increase of around 1.99%, confirming positive market sentiment.

In-Line / Cautious

A cautious in-line report may lead to muted stock movement, as investors weigh management's commentary on future guidance.

Miss

If GSK misses expectations, the stock could decline by approximately 0.83%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on vaccine production capacity and timelines.
2Details on consumer health product sales growth.
3Management's outlook on market conditions and competition.
4Insights into R&D progress and pipeline developments.
5Comments on operational efficiency improvements.